Journal Article
. 2018 Jan; 36(8):735-740.
doi: 10.1200/JCO.2017.74.6586.

PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer

Anne-Vibeke Lænkholm 1 Maj-Britt Jensen 1 Jens Ole Eriksen 1 Birgitte Bruun Rasmussen 1 Ann S Knoop 1 Wesley Buckingham 1 Sean Ferree 1 Carl Schaper 1 Torsten O Nielsen 1 Taryn Haffner 1 Torben Kibøl 1 Maj-Lis Møller Talman 1 Anne Marie Bak Jylling 1 Tomasz Piotr Tabor 1 Bent Ejlertsen 1 
  • PMID: 29369732
  •     24 citations


Purpose The PAM50-based Prosigna risk of recurrence (ROR) score has been validated in randomized clinical trials to predict 10-year distant recurrence (DR). The value of Prosigna for predicting DR was examined in a comprehensive nationwide Danish cohort consisting of postmenopausal women with hormone receptor-positive early breast cancer treated with 5 years of endocrine therapy alone. Patients and Methods Using the population-based Danish Breast Cancer Cooperative Group database, follow-up data were collected on all patients diagnosed from 2000 through 2003 who, by nationwide guidelines, were treated with endocrine therapy for 5 years. Primary tumor blocks from 2,740 patients were tested with Prosigna and, after determination of human epidermal growth factor receptor 2 (HER2) status, data from 2,558 hormone receptor-positive/HER2-negative samples were analyzed, including 1,395 node-positive patients. Fine and Gray models were applied to determine the prognostic value of ROR for DR. Results Median follow-up for recurrence was 9.2 years. Twenty-six percent of the node-positive patients were classified as low ROR (n = 359) with a DR risk of 3.5% (95% confidence interval [CI], 1.9% to 6.1%) versus a DR risk of 22.1% (95% CI, 18.6% to 25.8%) at 10 years for patients classified as high ROR (n = 648). Node-negative patients classified as low and high ROR had a risk of DR of 5.0% (95% CI, 2.9% to 8.0%) and 17.8% (95% CI, 14.0% to 22.0%), respectively. Luminal B tumors (n = 947; DR risk, 18.4% [95% CI: 15.7% to 21.3%]) had a significantly worse outcome than luminal A tumors (n = 1,474,;DR risk, 7.6% [95% CI: 6.1% to 9.2%]; P < .001). Conclusion Prosigna ROR score improved the prediction of outcome in this nationwide Danish population. In a real-world setting, Prosigna can reliably identify node-negative patients and a significant proportion of patients with one to three positive nodes who can be spared treatment with adjuvant chemotherapy.

Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Yixiao Feng, Mia Spezia, +15 authors, Guosheng Ren.
Genes Dis, 2018 Sep 28; 5(2). PMID: 30258937    Free PMC article.
Highly Cited. Review.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain.
Wesley L Cai, Celeste B Greer, +4 authors, Don X Nguyen.
BMC Med Genomics, 2020 Mar 08; 13(1). PMID: 32143622    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer.
Tian-Fu Li, Hui-Juan Zeng, +7 authors, Ying Lin.
Cancer Cell Int, 2020 Apr 24; 20. PMID: 32322170    Free PMC article.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Ryan J O Dowling, Kevin Kalinsky, +29 authors, Pamela J Goodwin.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337479    Free PMC article.
DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer.
Lei Lei, Xiao-Jia Wang, +2 authors, Yunyun Zhou.
Front Oncol, 2020 Jun 13; 10. PMID: 32528885    Free PMC article.
Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.
Gagan Gupta, Caroline Dasom Lee, +10 authors, Amy H Tang.
Ann Breast Cancer Ther, 2020 Jun 17; 4(1). PMID: 32542231    Free PMC article.
A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
Claire Bonneau, Antoine Eliès, +9 authors, Fatima Mechta-Grigoriou.
Breast Cancer Res, 2020 Jul 16; 22(1). PMID: 32665033    Free PMC article.
Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.
Stephanie Robertson, Balazs Acs, Michael Lippert, Johan Hartman.
Breast Cancer Res Treat, 2020 Jun 24; 183(1). PMID: 32572716    Free PMC article.
Network and Systems Medicine: Position Paper of the European Collaboration on Science and Technology Action on Open Multiscale Systems Medicine.
Blandine Comte, Jan Baumbach, +18 authors, Harald H H W Schmidt.
Netw Syst Med, 2020 Sep 22; 3(1). PMID: 32954378    Free PMC article.
LobSig is a multigene predictor of outcome in invasive lobular carcinoma.
Amy E McCart Reed, Samir Lal, +18 authors, Peter T Simpson.
NPJ Breast Cancer, 2019 Jul 03; 5. PMID: 31263747    Free PMC article.
Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20-23 March 2019: personalised treatments for patients with early breast cancer.
Consuelo Morigi.
Ecancermedicalscience, 2019 Jul 10; 13. PMID: 31281421    Free PMC article.
SEOM clinical guidelines in early stage breast cancer (2018).
F Ayala de la Peña, R Andrés, +7 authors, E Ciruelos.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30443868    Free PMC article.
Prognostic and predictive parameters in breast pathology: a pathologist's primer.
Kimberly H Allison.
Mod Pathol, 2020 Nov 07; 34(Suppl 1). PMID: 33154551
In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study.
Anna L V Johansson, Cassia B Trewin, +3 authors, Giske Ursin.
Breast Cancer Res, 2021 Feb 03; 23(1). PMID: 33526044    Free PMC article.
Retrospective Validation of a 168-Gene Expression Signature for Glioma Classification on a Single Molecule Counting Platform.
Paul Minh Huy Tran, Lynn Kim Hoang Tran, +8 authors, Jin Xiong She.
Cancers (Basel), 2021 Jan 29; 13(3). PMID: 33503830    Free PMC article.
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®.
Richard Buus, Zsolt Szijgyarto, +10 authors, Maggie Chon U Cheang.
NPJ Breast Cancer, 2021 Feb 14; 7(1). PMID: 33579961    Free PMC article.
Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Maroun Bou Zerdan, Maryam Ibrahim, +2 authors, Hazem I Assi.
Front Oncol, 2021 Mar 06; 10. PMID: 33665165    Free PMC article.
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer.
Allegra Freelander, Lauren J Brown, +4 authors, Elgene Lim.
Genes (Basel), 2021 Mar 07; 12(2). PMID: 33671468    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Molecular Biology in the Breast Clinics-Current status and future perspectives.
Vani Parmar, Nita S Nair, Purvi Thakkar, Garvit Chitkara.
Indian J Surg Oncol, 2021 May 18; 12(Suppl 1). PMID: 33994723    Free PMC article.
Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Breast Cancer Res Treat, 2021 Jun 01; 187(3). PMID: 34057651
Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan.
Lei Lei, Han-Ching Chan, Tzu-Pin Lu, Skye Hung-Chun Cheng.
Breast Cancer Res Treat, 2021 Jul 21;. PMID: 34282518